Rhythm Q4 loss narrower than  expected on higher IMCIVREE sales

Rhythm Pharmaceuticals

26/02/2026 12:21

Overview

Biopharmaceutical firm's Q4 net loss narrower than analyst expectations

Q4 net product revenue from IMCIVREE sales rose 12% sequentially to $57.3 mln

Company advancing Phase 3 trial for bivamelagon in acquired HO by year-end 2026

Outlook

Rhythm expects FDA approval for IMCIVREE in acquired HO by March 20, 2026

Company plans to announce topline data from setmelanotide Phase 3 trials in March 2026

Rhythm anticipates non-GAAP operating expenses of $385 mln to $415 mln for 2026

Result Drivers

INCREASED SALES - Q4 2025 net product revenue from IMCIVREE rose 12% sequentially, driven by Bardet-Biedl syndrome sales and more reimbursed therapy patients globally

EX-US REVENUE BOOST - Ex-US revenue increased 40% sequentially due to a one-time charge adjustment in France

Company press release: ID:nGNXKbFg5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$57.25 mln
Q4 Net Income
Beat
-$47.51 mln
-$53.21 mln (13 Analysts)
Q4 Operating Income
-$47.06 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $141.50, about 42.7% above its February 25 closing price of $99.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)